文献速递淋巴瘤造血干细胞移植与细胞治疗

纳武利尤单抗单药或联合ICE方案用于霍奇金淋巴瘤的应答适应性抗PD-1挽救治疗

Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE.
PubMed 文献 · Blood · 2022-01-01

这项2期试验评估PET适应性纳武利尤单抗单药或联合异环磷酰胺、卡铂和依托泊苷(NICE)作为复发/难治性经典型霍奇金淋巴瘤(cHL)的首个挽救治疗及自体造血细胞移植(AHCT)桥接方案。43例可评估毒性,42例可评估疗效。纳武利尤单抗单药后总缓解率(ORR)81%、完全缓解(CR)率71%;接受NICE的9例均缓解,8例(89%)达CR。方案治疗结束时ORR 93%、CR率91%。全部43例2年无进展生存(PFS)72%、总生存95%。

要点

  • PET适应性纳武利尤单抗单药或联合NICE方案耐受性好且有效,CR率高,多数患者无需化疗即桥接至AHCT。
  • 纳武利尤单抗单药后ORR 81%、CR率71%;NICE后9例均缓解,8例(89%)达CR。
  • 方案治疗结束时ORR 93%、CR率91%;直接桥接AHCT的33例2年PFS 94%(95%CI:78-98)。

核心结论

  • PET适应性序贯挽救治疗采用纳武利尤单抗单药或纳武利尤单抗联合NICE方案耐受性好且有效,CR率高,使多数患者无需化疗即桥接至AHCT。

研究设计与样本

  • 2期试验,评估PET适应性纳武利尤单抗单药或联合NICE方案作为复发/难治性经典型霍奇金淋巴瘤的首个挽救治疗及AHCT桥接方案。
  • 患者接受纳武利尤单抗240 mg每2周,最多6个周期(C);C6后达完全缓解(CR)者进入AHCT,任何时间出现疾病进展或C6后未达CR者接受NICE 2个周期。
  • 主要终点为方案治疗完成时按2014年Lugano分类的CR率;43例可评估毒性,42例可评估疗效。

主要发现

  • 34例接受纳武利尤单抗单药,9例接受纳武利尤单抗联合NICE;纳武利尤单抗或NICE后均未观察到非预期毒性。
  • 纳武利尤单抗单药后总缓解率(ORR)为81%,完全缓解(CR)率为71%。
  • 接受NICE的9例患者均缓解,其中8例(89%)达CR。
  • 方案治疗结束时ORR为93%,CR率为91%;33例直接桥接至AHCT,其中26例在纳武利尤单抗单药后桥接。
  • 全部43例治疗患者的2年无进展生存(PFS)为72%,总生存为95%;直接桥接AHCT的33例2年PFS为94%(95%CI:78-98)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This phase 2 trial evaluated PET-adapted nivolumab alone or in combination with ifosfamide, carboplatin, and etoposide (NICE) as first salvage therapy and bridge to autologous hematopoietic cell transplantation (AHCT) in relapsed/refractory (RR) classical Hodgkin lymphoma (cHL). Patients with RR cHL received 240 mg nivolumab every 2 weeks for up to 6 cycles (C). Patients in complete response (CR) after C6 proceeded to AHCT, whereas patients with progressive disease at any point or not in CR after C6 received NICE for 2 cycles. The primary endpoint was CR rate per the 2014 Lugano classification at completion of protocol therapy. Forty-three patients were evaluable for toxicity; 42 were evaluable for response. Thirty-four patients received nivolumab alone, and 9 patients received nivolumab+NICE. No unexpected toxicities were observed after nivolumab or NICE. After nivolumab, the overall response rate (ORR) was 81%, and the CR rate was 71%. Among 9 patients who received NICE, all responded, with 8 (89%) achieving CR. At the end of protocol therapy, the ORR and CR rates were 93% and 91%. Thirty-three patients were bridged directly to AHCT, including 26 after Nivo alone. The 2-year progression-free survival (PFS) and overall survival in all treated patients (n = 43) were 72% and 95%, respectively. Among 33 patients who bridged directly to AHCT, the 2-year PFS was 94% (95% CI: 78-98). PET-adapted sequential salvage therapy with nivolumab/nivolumab+NICE was well tolerated and effective, resulting in a high CR rate and bridging most patients to AHCT without chemotherapy. This trial was registered at www.clinicaltrials.gov #NCT03016871.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Mei MG, Lee HJ, Palmer JM, et al. Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE. Blood. 2022. PMID: 35316328. doi:10.1182/blood.2022015423

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。